ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-IA/JPW/GJG/ML	Serial No. 10/718,280
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo L. Castelhano et al.	
	Filing Date November 20, 2003	Group 1624

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1	5 2 9 6 4 8 4	3/22/94	Coghlan et al.			
	2	5 6 4 6 1 3 0	7/8/97	Shi			
	3	5 8 7 7 1 8 0	3/2/99	Linden et al.			
	4	5 8 8 9 0 2 6	3/30/99	Alanine et al.			
	5	5 9 3 5 9 6 4	8/10/99	Baraldi et al.			
	6	6 1 1 7 8 7 8	9/12/00	Linden			
	7	6 4 6 5 4 5 6	10/15/02	Springer et al.			
	8	6 9 1 6 8 0 4	7/12/05	Castelhano et al.			
	9	7 2 0 2 2 5 2	4/10/07	Wilson et al.			
	10	20 03 01 39 4 2 7	11/1/05	Castelhano et al.			
	11	20 03 02 29 0 6 7	12/11/03	Castelhano et al.			
	12	20 05 01 19 2 7 1	6/2/05	Castelhano et al.			
	13	20 04 00 82 5 9 9	4/29/04	Castelhano et al.			
	14	20 05 00 43 3 3 2	2/24/05	Castelhano et al.			
	15	20 08 00 70 9 3 6	3/20/08	Castelhano et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
	16	9 7 4 7 6 0 1	12/18/97	PCT				
	17	9 9 6 4 4 0 7	12/16/99	PCT				
	18	9 9 0 8 4 6 0	2/18/99	PCT				
	19	0 0 0 3 7 4 1	1/27/00	PCT				
	20	20 03 05 3 3 6 1	7/3/03	PCT				
	21	20 03 05 3 3 6 6	7/3/03	PCT				
	22	0 7 2 9 7 5 8	9/4/96	EPO				
	23	1 2 4 6 6 2 3	8/9/06	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	24	Hungarian Patent No. HU P9303515 (corresponds to WO 94/13676)
	25	Hungarian Patent No. HU P9501230 (corresponds to EP 0682027)
	26	Hungarian Patent No. HU P9602016 (corresponds to WO 95/19970)
	27	Hungarian Patent No. HU P9402829 (corresponds to WO 93/20078)
	28	Hungarian Patent No. HU P9602017 (corresponds to WO 95/19774)
	29	Abbracchio M., et al., (1997) "Modulation of Apoptosis by Nervous System: a Possible Role for the A3 Receptor", Ann. NY. Acad. Sci., 825: 11-22
	30	Aoyama S. et al. (2000) "Rescue of Locomotor Impairment in Dopamine D2 Receptor-Deficient Mice by an Adenosine A2a Receptor Antagonist" J.Neuroscience 20(15) : 5848-5852
	31	Avila, M.Y. (2001) "A1-A2a and A3-Subtype Adenosine receptors Modulate Intraocular Pressure in the Mouse" J. of Pharmacol. 241-245
	32	Baraldi, P.G. et al. (1996) "Pyrazolo [4,3-e]-1,2,4 triazolo [1,5-c]pyrimidine Derivatives: Potent and Selective A2a Adenosine Antagonists" J. Med. Chem. 39: 1164-1171
	33	Baraldi P., et al. (2000) "New potent and selective human adenosine A3 receptor antagonists", Tips, 21: 456-459
	34	Baraldi P., et al. "Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes", Curr. Pharm. Design 8: 2299-2332, 2002

EXAMINER	/Alton Pryor/	DATE CONSIDERED	10/20/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-1A/JPW/GJG/ML	Serial No. 10/718,280
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo L. Castelhano et al.	
	Filing Date November 20, 2003	Group 1624

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1	5 2 9 6 4 8 4	3/22/94	Coghlan et al.			
	2	5 6 4 6 1 3 0	7/8/97	Shi			
	3	5 8 7 7 1 8 0	3/2/99	Linden et al.			
	4	5 8 8 9 0 2 6	3/30/99	Alanine et al.			
	5	5 9 3 5 9 6 4	8/10/99	Baraldi et al.			
	6	6 1 1 7 8 7 8	9/12/00	Linden			
	7	6 4 6 5 4 5 6	10/15/02	Springer et al.			
	8	6 9 1 6 8 0 4	7/12/05	Castelhano et al.			
	9	7 2 0 2 2 5 2	4/10/07	Wilson et al.			
	10	20 03 01 39 4 2 7	11/1/05	Castelhano et al.			
	11	20 03 02 29 0 6 7	12/11/03	Castelhano et al.			
	12	20 05 01 19 2 7 1	6/2/05	Castelhano et al.			
	13	20 04 00 82 5 9 9	4/29/04	Castelhano et al.			
	14	20 05 00 43 3 3 2	2/24/05	Castelhano et al.			
	15	11 9 0 3 1 4 7	9/20/07	Castelhano et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	16	9 7 4 7 6 0 1	12/18/97	PCT				
	17	9 9 6 4 4 0 7	12/16/99	PCT				
	18	9 9 0 8 4 6 0	2/18/99	PCT				
	19	0 0 0 3 7 4 1	1/27/00	PCT				
	20	20 03 05 3 3 6 1	7/3/03	PCT				
	21	20 03 05 3 3 6 6	7/3/03	PCT				
	22	0 7 2 9 7 5 8	9/4/96	EPO				
	23	1 2 4 6 6 2 3	8/9/06	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	24	Hungarian Patent No. HU P9303515 (corresponds to WO 94/13676)
	25	Hungarian Patent No. HU P9501230 (corresponds to EP 0682027)
	26	Hungarian Patent No. HU P9602016 (corresponds to WO 95/19970)
	27	Hungarian Patent No. HU P9402829 (corresponds to WO 93/20078)
	28	Hungarian Patent No. HU P9602017 (corresponds to WO 95/19774)
	29	Abbracchio M., et al., (1997) "Modulation of Apoptosis by Nervous System: a Possible Role for the A3 Receptor", Ann. NY. Acad. Sci., 825: 11-22
	30	Aoyama S. et al. (2000) "Rescue of Locomotor Impairment in Dopamine D2 Receptor-Deficient Mice by an Adenosine A2a Receptor Antagonist" J.Neuroscience 20(15) : 5848-5852
	31	Avila, M.Y. (2001) "A1-A2a and A3-Subtype Adenosine receptors Modulate Intraocular Pressure in the Mouse" J. of Pharmacol. 241-245
	32	Baraldi, P.G. et al. (1996) "Pyrazolo [4,3-e]-1,2,4 triazolo [1,5-c]pyrimidine Derivatives: Potent and Selective A2a Adenosine Antagonists" J. Med. Chem. 39: 1164-1171
	33	Baraldi P., et al. (2000) "New potent and selective human adenosine A3 receptor antagonists", Tips, 21: 456-459
	34	Baraldi P., et al. "Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes", Curr. Pharm. Design 8: 2299-2332, 2002

EXAMINER	DATE CONSIDERED
/Alton Pryor/	10/20/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-IA/JPW/GJG/ML	Serial No. 10/718,280
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo Castelhano et al.	
	Filing Date November 20, 2003	Group 1624

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	35	Baraldi, P.G. et al., (1999) "A1 and A3 adenosine receptor agonists: an overview." *Expert Opinion on Therapeutic Patents*, 9(5):515-527
	36	Baraldi, P.G. et al., (2004) "Allosteric modulators for the A1 adenosine receptor." *Expert Opinion on Therapeutic Patents*, 14(1):71-79
	37	Baraldi, P.G. (2003) "Recent developments in the field of A2A and A3 adenosine receptor antagonists" Eur. J. Med. Chem. 38(4) 367
	38	Blazynski C., (1990) "Discrete Distributions of Adenosine Receptors in Mammalian Retina", Journal of Neurochemistry, 53: 648-655
	39	Borman, S. (2001) "A3 Receptors" C&EN, 79(7), 37
	40	Braas K.M., et al., (1987) "Endogenous adenosine and adenosine receptors localized to ganglion cells of the retina", Proceedings of the National Academy of Science, 84: 3906-3910
	41	Bradford M. M., (1976) "A Rapid and Sensitive Method for the Quantitaion of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", Anal. Biochem., 72: 248
	42	Bremer et al. (2002) "Therapy of Crohn's Disease in Childhood", Expert Opin. Pharmacother. 3(7): 809-825
	43	Broach, J. R. et al., (1983) "Vectors for high level, inducible expression of cloned genes in yeast", Inouye (ed)., Experimental Manipulation of Gene Expression. Academic Press, New York, 83-117
	44	Casavola V., et al., (1983) "Adenosine A3 receptor activation increases cystolic calcium concentration via calcium influx in A6 cells", Drug Development Research, 43 (1): 62
	45	Cheng, Y. and Prusoff, W. H. (1973) "Relationship Between The Inhibition Constant (Ki) And The Concentration Of Inhibitor Which Causes 50 Per Cent Inhibition (I50) Of An Enzymatic Reaction", Biochem. Pharmacol., 22: 3099-3109
	46	Christianson, T. W. et al., (1992) "Multifunctional yeast high-copy-number shuttle vectors", Gene, 110: 119-122
	47	Christofi, F. L. et al. (2001), "Differential Gene Expression of Adenosine A1, A2a, A2b, and A3 Receptors in the Human Enteric Nervous System", J. Comp. Neurol. 439(1): 46-64
	48	Coney, A. M. et al. (1998) "Role of Adenosine and its Receptors in the Vasodilation Induced in the Cerebral Cortex of the Rat by Systemic Hypoxia" J. Physiol. 509: 507-518
	49	Cooper, J. A. (1995) "Adenosine Receptor-induced Cyclic AMP Generation and Inhibition of 5-hydroxytryptamine release in Human Platelets" Br. J. Clin. Pharmacol. 40:43-50
	50	Corset, V. et al. (2000), "Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor", Nature, 407 (6805): 747-750
	51	Dubey, R. K. et al. (2001), "A2B Receptors Mediate the Antimitogenic Effects of Adenosine in Cardiac Fibroblasts", Hypertension 37: 716-721
	52	Duzic, E. et al, (1992) "Factors Determining the Specificity of Signal Transduction by Guanine Nucleotide-binding Protein-coupled Receptors", J. Biol. Chem., 267: 9844-9851
	53	Ezeamuzie C., et al. (1999), British Journal of Pharmacology, 127: 188-194
	54	Faivre, K. et al., (2001) "Suppression of Cellular Invasion by Activated G-Protein Subunits Gαo, Gαi1, and Gαi3 and Sequestration of Gβγ", Mol. Pharmacol. 60: 363-372
	55	Feoktistov, I. and Biaggioni, I., (1997) "Adenosine A2B Receptors", Pharmacol. Rev. 49(4): 381-402

EXAMINER	/Alton Pryor/	DATE CONSIDERED	10/20/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-IA/JPW/GJG/ML	Serial No. 10/718,280
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo Castelhano et al.	
	Filing Date November 20, 2003	Group 1624

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	56	Feoktistov, I. et al., (2002) "Differential Expression of Adenosine Receptors in Human Endothelial Cells", Circulation Research 90: 531-538
	57	Fishman P (2003) "Pharmacology and therapeutic applications of A3 receptor subtype" Curr. Top. Med. Chem. 3(4): 463-9
	58	Fozard J., et al., (1996) "Mast cell degranulation following adenosine A3 receptor activation in rats", European Journal of Pharmacology, 298: 293-297
	59	Franco M., et al., (1999) "Adenosine Regulates Renal Nitric Oxide Production in Hypothyroid Rats", Journal of the American Society of Nephrology, 1681-1688
	60	Gao, Z. et al., "A2B Adenosine and P2Y2 Receptors Stimulate Mitogen-activated Protein Kinase in Human Embryonic Kidney-293 Cells" J. Bio. Chem. (1999) 274(9): 5972-5980
	61	Ghiardi, G. J. et al. (1999) "The Purine Nucleoside Adenosine in Retinal Ischemia-Reperfusion Injury" Vision Research 39:2519-2535
	62	GenBank accession # S46950
	63	GenBank accession numbers S45235 and S56143
	64	Grant, M.B. et al., (2001) "Proliferation, Migration, and ERK Activation in Human Retinal Endothelial Cells through A2B Adenosine Receptor Stimulation", Invest. Opthalmol. Vis. Sci. 42(9): 2068-2073
	65	Guerra L., et al., (1998) "Adenosine A3 receptor activation increases cytosolic calcium influx in A6 cells", Nephrology Diálisis Transplantation, 13 (6): A5
	66	Guo, Y. et al., (2001) "Targeted deletion of A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning." *J Mol Cell Cardiol*, 33:825-830
	67	Haynes, J. Jr. et al., (1999) "5-(N-ethylcarboxamido) adenosine desensitizes the A2b-adenosine receptor in lung circulation", Am. J. Physiol. 276(6): H1877-H1883
	68	Herndon, J.L. et al., (1992) Herndon, J.L. et al., "Ketanserin Analogs: Structure-Affinity Relationships for 5-HT2 and 5-HT1C Serotonin Receptor Binding", J. Med. Chem. 35(26): 4903-4910
	69	Hoeschst India Ltd., India "Pharmacologically active pyrimido "[4,5-b]indoles and their salts." Database accession No. 106:84629 HCA XP002121648
	70	Kanda, T. et al. (1998) "Adenosine A2a Receptors Modify Motor Function in MPTP-treated Common - Marmosets" Neuroreport 9: 2857-2860
	71	Kanda, T. et al. (2000) "Combined Use of the Adenosine A2a Antagonist KW-6002 with L-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but not Dyskensia in MPTP-Treated Monkeys" Experimental Neurology 162: 321-327
	72	Kang, Y. et al., (1990) "Effects of Expression of Mammalian Gα and Hybrid Mammalian-Yeast Gα Proteins on the Yeast Pheromone Response Signal Transduction Pathway", Mol. Cell. Biol., 10: 2582-2590
	73	Kiichiro, K. et al. "Synthesis of pyrazinecarboxylic acid derivs. - (II) derivs. of 3-aminopyrazinecarboxylic acid" Chem. Abstracts 56:8713

EXAMINER	DATE CONSIDERED
/Alton Pryor/	10/20/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-IA/JPW/GJG/ML	Serial No. 10/718,280
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo Castelbano et al.	
	Filing Date November 20, 2003	Group 1624

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	74	Kiritsy, J.A. et al., (1978) "Synthesis and Quantitative Structure-Activity Relationships of Some Antibacterial 3-Formylrifamycin SV N-(4-Substituted phenyl) piperazinoacethydrazones" J. Med. Chem. 21(12): 1301-1307
	75	Klumpp, D.A. et al., (1999) "Synthesis of Aryl-Substituted Piperidines by Superacid Activation of Piperidones" J. Org. Chem. 64(18): 6702-6705
	76	Knutsen, L.J.S. et al. (2001) Curr. Opin. Invest. Drugs 2(5):668-673
	77	Kopf, S.R. et al. (1999) "Adenosine and Memory Storage: Effect of A1 and A2 Receptor Antagonists" Psychopharmacology 146:214-219
	78	Li, J.M. et al. (1998) "Adenosine A2a Receptors Incrase Arterial Endothelial Cell Nitric Oxide" J. Surg. Res. 80:357-364
	79	Linden, J. et al., (1998) "The Structure and Function of A1 and A2B Adenosine Receptors" Life Sciences 62(17-18): 1519-1524
	80	Meade et al., PubMed Abstract (Life Sci. 69(11):1225-40) August 2001
	81	Mitchell, C.H. et al., "Adenosine A3 Receptor Activation Reduces Cell Volume and Activates Cl^- Current in Human Ciliary Epithelial Cells", *FASEB J*, A134 (Abstract only)
	82	Michell, C.H. (1999) "A3 adenosine receptors regulate Cl-channels of nonpigmented ciliary epithelial cells" Am. J. Physiol. 276: C659-C666
	83	Mirabet, M. et al., (1999) "Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation" J. Cell. Sci. 112(4): 491-502
	84	Montesinos, M.C. et al. (2002) "Adenosine Promotes Wounds Healings and Mediates Angiogenesis in Response to Tissue Injury Via Occupancy of A2a Receptors" American Journal of Pathology 160(6):2009-2018
	85	Müller, C.E. et al., "Imidazo [2,1-i] purin-5-ones and Related Tricyclic Water-Soluble Purine Derivatives: Potent A2A- and A3-Adenosine Receptor Antagonists", (2002) J. Med. Chem. 45(16): 3440-3450
	86	Müller, C.E. (2001) "A3 Adenosine Receptor Antagonists" Mini Reviews in Med. Chem. 1(4): 339
	87	Nagarathnam, D. et al., (1998) "Design and Synthesis of Novel α1a Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia", J. Med. Chem. 41(26): 5320-5333
	88	Nishiyama, A. et al. (2001) "Interactions of Adenosine A1 and A2 a Receptors on Renal Microvascular Reactivity" Am. J. Physiol. Renal Physiol. 280:F406-F414

EXAMINER	/Alton Pryor/	DATE CONSIDERED	10/20/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-IA/JPW/GJG/ML	Serial No. 10/718,280
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo Castelhano et al.	
	Filing Date November 20, 2003	Group 1624

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	89	Ohana G., et al., (2001) "Differential Effect of Adenosine on Tumor and Normal Cell Growth: Focus on the A3 Adenosine Receptor", Journal of Cellular Physiology, 186: 19-23
	90	Phillips, J.W. (1995) "The Effects of Selective A1 and A2a Adenosine Receptor Antagonists on Cerebral Ischemic Injury in the Gerbil
	91	Polosa (2002) "Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease", Eur. Respir. Journal 20,488-496
	92	Priego, E.-M. et al., "Pyrido [2,1-f]purine-2,4-dione Derivatives as a Novel Class of Highly Potent Human A3 Adenosine Receptor Antagonists", (2002) J. Med. Chem., 45(16): 3337-3344
	93	Ralevic, V. And Burnstock, G., (1998) "Receptors for Purines and Pyrimidines", Pharmacol. Rev. 50(3): 413-492
	94	Regnauld, K. et al., (2002) "G-protein αolf subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells", Oncogene 21(25): 4020-4031
	95	Regulation of Downstream Effectors By GPCRs, (1999) FASEB J., Abstracts 147.1-147.6
	96	Reshkin J., et al., (2000) "Activation of A3 Adenosine Receptor Induces Calcium Entry and Chloride Secretion in A6 Cells", J. Membrane Biol., 178: 103-113
	97	Robinson, "Medical Therapy of Inflammatory Bowel Disease for the 21st Century", Eur J Surg. Suppl 582:90-98, 1998
	98	Sawynok J., et al., (1997) "Adenosine A3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine", European Journal of Pharmacology, 333: 1-7
	99	Shiozaki, S. et al. (1999) "Actions of Adenosine A2a Receptor Antagonist KW-6002 on Drug-induced Catalepsy and hypokinesia Caused by Reserpine of MPTP" Psychopharmacology 147:90-95
	100	Simone, Oncology: Introduction Cecil Textbook of Medicine, 20th Edition, Vol. 1, pp. 1004-1010, 1996
	101	Singh et al., "Immune therapy in inflammatory bowel disease and models of colitis", British Journal of Surgery, 88: 1558-1569, 2001
	102	Strohmeier, G. R. et al., (1995) "The A2b Adenosine Receptor Mediates cAMP Responses to Adenosine Receptor Agonists in Human Intestinal Epithelia", J. Bio. Chem., 270: 2387-2394
	103	Svenningsson, P. et al. (1999) "Distribution, Biochemistry and Function of Striatal Adenosien A2a Receptors" Prog. Neurobiol. 59(4):355-396
	104	Tanaka, H. et al.' "Preparation and formulation of fused pyrimidine compounds as CRF receptor antagonists." Database accession no. 129:109098 HCA XP002121647
	105	Taomoto, M. ety al. (2000) "Localization of Adenosine A2 Receptor in Retinal Development and Oxygen-Induced Retinopathy" Investigative Ophthalmology & Visual Science 41(1):230-243
	106	Van Niel, M.B. et al., "Fluorianation of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl) indoles Gives Selective Human 5-Htid Receptor Ligands with Improved Pharmokinetic Profiles" J. Med. Chem. (1999) 42(12): 2087-2104
	107	Varani, K. et al. (1998) "[^{3}H]-SCH 58261 Labelling of Functional A2a Adenosine Receptors in Human Neutrophil Membranes" Br. J. Pharmacol. 123:1723-1731

EXAMINER	DATE CONSIDERED
/Alton Pryor/	10/20/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-1A/JPW/GJG/ML	Serial No. 10/718,280
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo Castelhano et al.	
	Filing Date November 20, 2003	Group 1624

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	108	Von Lubitz D., et al., (1999) "Stimulation of Adenosine A3 Receptors in Cerebral Ischemia", Ann. NY. Acad. Sci., 890: 93-106
	109	Von Lubitz, D., et al., (1999) "Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects", European Journal of Pharmacology, 367: 157-163
	110	West, R.A. et al. (1961) "2-alkyl(aryl)-and 2,7-dimethyl-4-substituted aminopyrrolo[2,3—d]pyrimidines." *J. Org. Chem.*, 26:3809-3812
	111	Yan, Luo et al. (2003) Expert Opinion on Emerging Drugs, vol. 8, no. 2 pp. 537-576
	112	Yao Y., et al., (1997) "Adenosine A3 Receptor Agonists Protect HL-60 and U-937 Cells from Apoptosis Induced by A3 Antagonists", Biochemical And Biophysical Research Communications, 232: 317-322
	113	Zhao Z., et al., (2000) "A role for the A3 Adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice", Biochimica et Biophysica Acta, 1500: 280-290
	114	International Search Report issued in PCT International Application No. PCT/US99/12135, filed June 1, 1999
	115	International Search Report issued in PCT International Application No. PCT/US00/32702, filed December 1, 2000
	116	International Search Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001
	117	International Search Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002
	118	International Search Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002
	119	International Search Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002
	120	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US99/121358
	121	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US00/32702
	122	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001
	123	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002
	124	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002
	125	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002
	126	Supplemental European Search Report; for EP Application No. 02 80 5676; issued 2/7/2005
	127	Partial European Search Report for EP Application No. 06 01 6543.8; completed 10/4/2006
	128	Partial European Search Report; for EP Application No. 01 99 7029; completed 12/21/2004

EXAMINER	DATE CONSIDERED
/Alton Pryor/	10/20/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-1A/JPW/GJG/NDP	Serial No. 10/718,280
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo Castelhano et al.	
	Filing Date November 20, 2003	Group

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
/A.P./		10 4 9 7 4 5 1	5/27/04	Castelhano et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER /Alton Pryor/	DATE CONSIDERED 10/20/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Arlindo L. Castelhano et al.
Serial No.: 10/718,280
Filed: November 20, 2003
Exhibit A

B

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-1A/JPW/GJG/JBC	Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo Castelhano et al.	
	Filing Date Herewith	Group

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
AM		3 0 3 7 9 8 0	6/5/62	Hitchings, G.H. et al.;			
		3 9 1 0 9 1 3	10/7/75	Kim, et al.;			
		5 2 0 8 2 4 0	5/4/93	Peet, et al.;			
		5 4 0 9 9 3 0	4/25/95	Spada, A.P. et al.;			
		5 5 1 6 8 9 4	5/14/96	Reppert, S.M.;			
		5 5 8 0 8 7 0	12/3/96	Barker, A.J. et al.;			
		5 6 3 9 9 1 3	6/17/97	Lidor et al.;			
		5 6 4 6 1 5 6	7/8/97	Jacobson et al.;			
		5 6 8 1 9 4 1	10/28/97	Cook, P.D. et al.;			
		5 7 1 0 1 5 8	1/20/98	Myers, M.R. et al.;			
		5 7 1 4 4 9 3	2/3/98	Myers, M.R. et al.;			
		5 7 2 1 2 3 7	2/24/98	Myers, M.R. et al.;			
		5 7 4 7 4 9 8	5/5/98	Schnur, R.C. et al.;			
		5 7 8 0 4 5 0	7/14/98	Shade, D.L. et al.;			
		5 7 8 0 4 8 1	7/14/98	Jacobson et al.;			
		5 8 3 4 6 0 9	11/10/98	Horne, D.A. et al.;			
		5 8 7 7 2 1 8	3/2/99	Herzig et al.;			
		5 8 7 7 2 2 1	3/2/99	Cohen et al.;			
		5 8 8 0 1 5 9	3/9/99	Herzig et al.;			
		5 9 1 4 3 4 9	6/22/99	Cohen et al.;			
		5 9 6 2 4 5 8	10/5/99	Lohmann et al.;			
		5 9 9 4 4 0 8	11/30/99	Cohen et al.;			
AM		6 1 0 3 8 9 9	8/15/00	Horne, D.A. et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
AM	WO	9 3 2 0 0 7 8	10/14/93	PCT;				
MH	WO	9 4 1 3 6 7 6	6/23/94	PCT;				
MH	WO	9 4 1 7 0 9 0	8/4/94	PCT;				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER Alton Wyatt DATE CONSIDERED 3/3/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office **INFORMATION DISCLOSURE CITATION** (Use several sheets if necessary)	Atty. Docket No. 60390-IA/JPW/GJG/JBC	Serial No. Not Yet Known
		Applicants: Arlindo Castelhano et al.	
		Filing Date Herewith	Group

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

AN	WO	9	4	1	9	3	4	9	9/1/94	PCT;				
	WO	9	4	2	4	1	3	6	10/27/94	PCT;				
	WO	9	5	1	1	6	8	1	5/4/95	PCT;				
	WO	9	5	1	8	6	1	7	7/13/95	PCT;				
	WO	9	5	1	9	7	7	4	7/27/95	PCT;				
	WO	9	5	1	9	9	7	0	7/27/95	PCT;				
	WO	9	5	2	0	5	9	7	8/3/95	PCT;				
	WO	9	6	1	9	4	7	8	6/27/96	PCT;				
	WO	9	7	0	2	2	6	6	1/23/97	PCT;				
	WO	9	7	0	5	1	3	8	2/13/97	PCT;				
	WO	9	7	3	3	8	7	9	9/18/97	PCT;				
	WO	9	8	0	7	7	2	6	2/26/98	PCT;				
	WO	9	8	0	8	3	8	2	3/5/98	PCT;				
	WO	9	8	2	2	4	6	5	5/28/98	PCT;				
	WO	9	8	2	9	3	9	7	7/9/98	PCT;				
	WO	9	8	5	7	6	5	1	12/23/98	PCT;				
	WO	9	9	0	6	0	5	3	2/11/99	PCT;				
	WO	9	9	3	3	8	1	5	7/8/99	PCT;				
	WO	9	9	4	2	0	9	3	8/26/99	PCT;				
	WO	9	9	6	2	5	1	8	12/9/99	PCT;				
	WO	0	1	3	9	7	7	7	6/7/01	PCT (Exhibit 1);				
	WO	02	0	5	7	2	6	7	7/25/02	PCT;				
	WO	03	0	4	8	1	2	0	6/12/03	PCT (Exhibit 2);				
	EP	0	3	2	2	2	4	2	6/28/89	EPO;				
	EP	0	5	1	4	5	4	0	11/25/92	EPO;				
	EP	0	6	8	2	0	2	7	11/15/95	EPO;				
	EP	0	7	2	9	7	5	8	9/4/96	EPO;				
AN	EP	0	7	7	3	0	2	3	5/14/97	EPO;				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER Alton Pryor	DATE CONSIDERED 3/3/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-1A/JPW/GJC/JBC	Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo Castelhano et al.	
	Filing Date Herewith	Group

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
AM	GB	0 9 1 5 3 0 3	1/9/63	Great Britain;				
	DE	3 1 4 5 2 8 7	5/19/93	Germany;				
	IN	0 1 5 7 2 8 0	2/22/86	India;				
AM	JP	09 2 9 1 0 8 9	5/11/999	Japan;				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	Abbracchio M., et al., (1999) "Brain Adenosine Receptors as Targets for Therapeutic Intervention in Neurodegenerative Diseases", Ann. NY. Acad. Sci, 890: 79-92;
	Banker, G.S. et al., Modern Pharmaceutics, 3rd ed., Marcel Dekker, New York, 1996, page 596;
	Barrett, R.J. (1996) "Realizing the Potential of Adenosine-Receptor-Based Therapeutics" Proc. West. Pharmacol. Soc. 39: 61-66;
	Barrett, R.J. et al., "N-0861 selectively antagonizes adenosine A1 receptors in vivo" European J. Pharmacology (1992) 216: 9-16;
	Brand A., et al., (2001) "Adenosine A1 and A3 receptors mediate inhibition of synaptic transmission in rat cortical neurons", Neuropharmacology, 40: 85-95;
	Bundy, G.L. et al. (1995) "Synthesis of Novel 2,4-Diaminopyrrolo-[2,3-d]pyrimidines with Antioxidant, Neuroprotective, and Antiasthma Activity" J. Med. Chem. 38: 4161-4163;
	Campbell, R.M. et al., "Selective A_1-Adenosine Receptor Antagonists Identified Using Yeast *Saccharomyces Cerevisiae* Functional Assays" Bioorg. & Med. Chem. Lett. (1999) 9(16): 2413-2418;
	Chen, Y. L., et al., "Synthesis and Oral Efficacy of a 4-(Butylethylamino)pyrrolo[2,3-*d*]pyrimidine: A Centrally Active Corticotropin-Releasing Factor$_1$ Receptor Antagonist", (1997) J. Med. Chem., 40: 1749-1754;
	Cummings, J. et al., "Antagonism of the Cardiodepressant Effects of Adenosine during Acute Hypoxia" Academic Emergency Medicine (2000), 7(8): 618-624;
	DeNinno, M.P. in Annual Reports in Medicinal Chemistry, Vol. 33, (Academic Press: San Diego, 1998), pp. 111-120;
	Dhainaut, A. et al., "New Purines and Purine Analogs as Modulators of Multidrug Resistance" J. Med. Chem. (1996) 39: 4099-4108;
	Dooley, M.J. et al., "Theoretical Structure-Activity Studies of Adenosine A1 Ligands: Requirements for Receptor Affinity" *Bioorg. Med. Chem.* (1996), 4(6): 923-934;
	Feoktistove, I. et al., (1998) "Adenosine A_{2B} receptors: a novel therapeutic target in asthma?", TiPS 19: 148-153;
AM	Gao, E. et al., "Adenosine A1 Receptor Antagonist Prolongs Survival in the Hypoxic Rat" *J. Cardiovascular Pharm.* (2001) 38: 384-394;

EXAMINER	A Han Nyer	DATE CONSIDERED	3/3/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-IA/JPW/GJG/JBC	Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo Castelhano et al.	
	Filing Date Herewith	Group

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AW		Hart, H. et al., Organic Chemistry, A Short Course, (Houghton Mifflin: 1995), p. 121;
		Iwamura, H. et al. (1996) "Quantitative Aspects of the Receptor Binding of Cytokinin Agonists and Antagonists" J. Med. Chem., 26: 838-844;
		Jacobson K.A., et al., (1998) "Adenosine A3 receptors: novel ligands and paradoxical effects", TiPS, 19:184-191;
		Jacobson K.A., et al., (1997) "Pharmacological Characterization of Novel A3 Adenosine Receptor-selective Antagonists", Neuropharmacology, 36 (9): 1157-1165;
		Jorgensen, A. et al. (1985) "Synthesis of 7H-Pyrrolo[2,3-d]pyrimidin-4-amines" Liebigs, Ann. Chem., Pages 142-148;
		Kaiser, S.M. and R.J. Quinn (1999) "Adenosine receptors as potential therapeutic targets" Drug Discovery Today 4(12): 542-551;
		Kiichiro, K. et al. "Synthesis of pyrazinecarboxylic acid derivs. - (II) derivs. of 3-aminopyrazinecarboxylic acid" (1961) Yakugaku Zasshi 81: 1650-1653;
		Lee T., et al., (1999) "Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors", 72nd Scientific Sessions of the American Heart Association, Atlanta, GA, p.197;
		Lee T., et al., (2000) "Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors", Am. J. Physiol. Renal Physiol., 278: F380-F387;
		Marx, D. et al. (2001) "Therapy of Bronchial Asthma with Adenosine Receptor Agonists or Antagonists" Drug News Perspect. 14(2): 89-100;
		Mautner, H.G., (1961) "Potential Deoxyribonucleic Acid Cross-linking Agents. 8,8'-Bispurines", J. Org. Chem. 26(6):1914-1917;
AW		Muller, C. E. et al. (1990) "7-Deaza-2-phenyladenines: Structure-Activity Relationships of Potent A1 Selective Adenosine Receptor Antagonists" J. Med. Chem., 33: 2822-2828;

EXAMINER A Horlacher	DATE CONSIDERED 3/3/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-IA/JPW/GJG/JBC	Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo Castelhano et al.	
	Filing Date Herewith	Group

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BM		Muller, C.E. et al. (1996) "Chiral Pyrrolo[2,3-d]pyrimidine and Pyrimido[4,5-b]indole Derivatives: Structure-Activity Relationships of Potent, Highly Stereoselective A_1-Adenosine Receptor Antagonists" J. Med. Chem., 39: 2482-2491;
		Muller, C. E. and Stein, B. (1996) "Adenosine Receptor Antagonists: Structures and Potential Therapeutic Applications", Current Pharmaceutical Design, 2: 501-530;
		Muller, C. E.(1997) "A_1-Adenosine Receptor Antagonists", Exp. Opin. Ther. Patents 7(5): 419-440;
		Muller, C. E., et al., (1997) "Synthesis and Structure-Activity Relationships of 3,7-Dimethyl-1-propargylxanthine Derivatives, A_{2A}-Selective Adenosine Receptor Antagonists", J. Med. Chem., 40: 4396-4405;
		Nishiyama, A. et al., "Adenosine A1 Receptor Antagonist KW-3902 Prevents Hypoxia-Induced Renal Vasoconstriction" *J. Pharm. Exp. Ther.* (1999), 291: 988-993;
		Nyce, J. W. and Metzger, J.W., (1997) "DNA antisense therapy for asthma in an animal model", Nature, 385: 721-725;
		Pichler, H. et al. "Synthese von 7-unsubstituierten 7H-Pyrrolo[2,3-d] pyrimidinen", (1986) Liebigs Ann. Chemie., 9: 1485-1505;
		Seela, F., and Lupke, U.,"Mannich-Reaktion am 2-Amino-3,7-dihydropyrrolo [2,3-*d*] pyrimidin-4-on, dem Chromophor des Ribonucleosids "Q" (1977) Chem. Ber. 110: 1462-1469;
		Shan, Daxian et al., J. Pharmaceutical Sci., (1997) 86:765-767;
		Szkotak, A.J. et al., "Regulation of K^+ current in human airway epithelial cells by exogenous and autocrine adenosine" *Am. J. Physiol. Cell Physiol.* (2001), 281: C1991-C2002;
		Venugopalan, B. et al. (1998) "Synthesis of 6,7-Dimethoxypyrimido[4,5-b]-indoles as Potential Antihypertensive Agents" J. Heterocyclic Chem., 25: 1633-1639;
		Welch, W.J. "Adenosine type 1 receptor antagonists in fluid retaining disorders" Expert Opin. Investig. Drugs (2002), 11(11): 1553-1562;
AW		West, R. A. et al. (1961) "2-Alkyl(aryl)-and 2,7-Dimethyl-4-substituted Aminopyrrolo[2,3-d]pyrimidines" J. Org. Chem., 26: 3809-3812;

EXAMINER Alton Pryor	DATE CONSIDERED 3/3/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-IA/JPW/GJG/JBC	Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Arlindo Castelhano et al.	
	Filing Date Herewith	Group

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
AWP		20 02 00 28 7 8 2	3/7/02	Castelhano et al. (Exhibit 3, claims only);			
		20 02 00 58 6 6 7	5/16/02	Castelhano et al. (Exhibit 4, claims only);			
		20 03 00 36 5 4 5	2/20/03	Castelhano et al. (Exhibit 5, claims only);			
		20 02 00 94 9 7 4	4/17/03	Castelhano et al. (Exhibit 6, claims only);			
		20 03 00 73 7 0 8	4/17/03	Castelhano et al. (Exhibit 7, claims only);			
		09 4 5 4 0 7 4	12/2/99	Castelhano et al. (Exhibit 8, claims only);			
		09 4 5 4 0 7 5	12/2/99	Castelhano et al. (Exhibit 9, claims only);			
		10 0 1 0 0 9 2	11/30/01	Castelhano et al.;			
AWP		20 03 00 45 5 3 6	3/6/03	Castelhano et al. (Exhibit 10, claims only);			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AWP		Williams, E. F. et al., "Nucleoside transport sites in a cultured human retinal cell line established by SV-40 T antigen gene", (1994) Current Eye Research, 13: 109-118;
		Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, 5th ed., Volume I: Principles and Practice, John Wiley & Sons, 1995, pages 975-977;
		Woods, C. L. and Blazynski, C. (1991) "Characterization of Adenosine A_1-receptor Binding Sites in Bovine Retinal Membranes", Experimental Eye Research, 53: 325-331; and
AWP		Zhao, Z. et al., "Bioactivation of 6,7-Dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) to Reactive Intermediates that Bind Covalently to Macromolecules and Produce Genotoxicity" Chem. Res. Toxicol., (1996) 9: 1230-1239.

EXAMINER Alton Pryor DATE CONSIDERED 3/3/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.